Drug Initiative

Is the FDA ignoring heart risks from high triglycerides in the face of mounting evidence to the contrary?

The lives of millions of Americans are potentially at risk.

The EPA Drug Initiative (EPADI) urges the FDA to thoughtfully consider new and almost irrefutable proof that high triglycerides are a significant risk factor contributing to cardiovascular disease-related death and morbidity.

Recently, two independent studies were published in the prestigious New England Journal of Medicine (NEJM), both drawing the same conclusion: that reducing serum triglycerides to accepted, safe levels resulted in a 40% decrease in cardiovascular risk. These trial results are being universally hailed as groundbreaking, as they focus on people having a certain gene mutation, which elegantly eliminates all cardiovascular disease risk factors other than serum triglyceride levels. Both studies—from well-respected researchers—have caught the attention of the world, with the results being published by prominent news media including the New York Times and Forbes.

Read the Full Story

I've been taking Vascepa for 5 months and I can report the results have been excellent. My triglycerides went from 440 mg/dL to under 190 mg/dL. I've also noticed another benefit besides lower Triglycerides which is less eye inflammation. I've suffered from Dry Eye Syndrome for over 30 year and since taking Vascepa my eyes are much improved and I haven't had the need for eye drops.

John Cappello
Middlebury, CT
Back To Top